European Commission approves Sanofi's VaxRabeo rabies vaccine for all age groups

The first marketing authorisation for Sanofi's Vero-cell rabies vaccine covers pre-exposure and post-exposure prophylaxis across all ages, supported by comparative immunogenicity and safety data.
On 19 November 2026, Sanofi announced that the European Commission had granted marketing authorisation to VaxRabeo, an inactivated rabies vaccine produced using Vero-cell technology, for pre-exposure and post-exposure prophylaxis in people of all ages.
Clinical studies showed protective antibody responses comparable with established Sanofi rabies vaccines and a similar safety profile, while the product offers improved thermostability and a five-year shelf life.
Field | Content |
Alert Type | Approval |
Product | VaxRabeo |
Active Ingredient or Technology | Inactivated rabies virus strain Wistar vaccine produced using Vero-cell technology |
Company or Marketing Authorisation Holder | Sanofi |
Regulatory Authority | European Commission |
Approval Type | Initial European Union marketing authorisation |
Approved Indication | Pre-exposure and post-exposure prophylaxis against rabies |
Patient Population | All age groups requiring rabies pre-exposure or post-exposure prophylaxis |
Therapy Area(s) | Vaccines; infectious diseases; rabies prevention |
What Was Approved | The European Commission authorised VaxRabeo for rabies prevention before or after potential exposure across all age groups, representing the product's first marketing authorisation. |
Supporting Evidence | The clinical programme compared VaxRabeo with established Sanofi rabies vaccines Verorab and Imovax Rabies. Studies showed comparable protective antibody responses in pre-exposure regimens, similar immunogenicity after exposure and a safety profile consistent with existing vaccines. |
Clinical Significance | The vaccine provides an additional authorised option for rabies prevention in adults and children, including post-exposure vaccination schedules. It is not a treatment for symptomatic rabies. |
Regulatory Context | The authorisation followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on 17 September 2026 and represents a final European Commission decision rather than an advisory recommendation. |
Key Takeaway | VaxRabeo has received its first marketing authorisation in the European Union for both pre-exposure and post-exposure rabies prophylaxis in all ages. |
What to Watch | European availability, vaccination programme adoption, product supply and implementation of authorised prophylaxis schedules. |
Primary Source | https://www.sanofi.com/en/media-room/press-releases/2026/2026-11-19-06-00-00-3406292 |
Approval Date | Announced 19 November 2026; exact Commission decision date not specified in the cited announcement |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments